Personalized medicine for diabetes

Journal of Diabetes Science and Technology

Volumn 2, Issue 3, 2008, Pages 335-341

  Klonoff, David C ^a  

^a Mills Peninsula Health Services   (United States)

Author keywords

Diabetes; Genetics; Genomics; Pharmacogenomics. personalized medicine

Indexed keywords

EID: 79955153852     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200301     Document Type: Review

References (81)

1. Woodcock J. The prospects for "personalized medicine" in drug development and drug therapy. Clin Pharmacol Ther. 2007;81:164-9.
2. O'Rahilly S, Barroso I, Wareham NJ. Genetic factors in type 2 diabetes: the end of the beginning? Science. 2005;307:370-3.
3. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest. 2007;117:1226-9.
4. Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, Gnasso A, Grupillo M, Lauro R, Hribal ML, Perticone F, Marchetti P. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:2334-9.
5. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117:1422-31.
6. Collins CD, Purohit S, Podolsky RH, Zhao HS, Schatz D, Eckenrode SE, Yang P, Hopkins D, Muir A, Hoffman M, McIndoe RA, Rewers M, She JX. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul Pharmacol. 2006;45:258-67.
7. Hoffman EP. Skipping toward personalized molecular medicine. N Engl J Med. 2007;357:2719-22.
8. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des. 2007;13:2832-6.
9. Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M, Windemuth A, de Leon J. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol Psychiatry. 2007;12:474-82.
10. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL, Shafa F, Stuart JM, Altman RB. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J. 2001;1:167-70.
11. Bozkurt O, de Boer A, Grobbee DE, Heerdink ER, Burger H, Klungel OH. Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Mol Diagn Ther. 2007;11:291-302.
12. El-Sohemy A. Nutrigenetics. Forum Nutr. 2007;60:25-30.
13. Kaput J, Dawson K. Complexity of type 2 diabetes mellitus data sets emerging from nutrigenomic research: a case for dimensionality reduction? Mutat Res. 2007;622:19-32.
14. In't Veld P, Lievens D, De Grijse J, Ling Z, Van der Auwera B, Pipeleers-Marichal M, Gorus F, Pipeleers D. Screening for insulitis in adult autoantibody-positive organ donors. Diabetes. 2007;56:2400-4.
15. Mojiminiyi OA, Abdella NA. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest. 2007;67:215-25.
16. Shaibi GQ, Cruz ML, Weigensberg MJ, Toledo-Corral CM, Lane CJ, Kelly LA, Davis JN, Koebnick C, Ventura EE, Roberts CK, Goran MI. Adiponectin independently predicts metabolic syndrome in overweight Latino youth. J Clin Endocrinol Metab. 2007;92:1809-13.
17. Teixeira RE, Malin S. The next generation of artificial pancreas control algorithms. J Diabetes Sci Technol 2008;2:105-12.
18. Petrasek D. Systems biology: the case for a systems science approach to diabetes. J Diabetes Sci Technol 2008;2:131-4.
19. Eising S, Svensson J, Skogstrand K, Nilsson A, Lynch K, Andersen PS, Lernmark A, Hougaard DM, Pociot F, Norgaard-Pedersen B, Nerup J. Type 1 diabetes risk analysis on dried blood spot samples from population-based newborns: design and feasibility of an unseected case-control study. Paediatr Perinat Epidemiol. 2007;21:507-17.
20. Hattersley AT. Prime suspect: the TCF7L2 gene and type 2 diabetes risk. J Clin Invest. 2007;117:2077-9.
21. Savage DA, Bain SC, McKnight AJ, Maxwell AP. Gene discovery in diabetic nephropathy. Curr Diab Rep. 2007;7:139-145.
22. Fox CS, Heard-Costa N, Cupples LA, Dupuis J, Vasan RS, Atwood LD. Genome-wide association to body mass index and waist circumference: the Framingham Heart Study 100K project. BMC Med Genet. 2007;8 Suppl 1:S18.
23. Staevaq-Vieira T, Peakman M, von Herrath M. Translational minireview series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol. 2007;148:17-31.
24. Harrison LC. The prospect of vaccination to prevent type 1 diabetes. Hum Vaccin. 2005:1143-50.
25. Jermendy G, Ruggenenti P. Preventing microalbuminuria in patients with type 2 diabetes. Diabetes Metab Res Rev. 2007;23:100-10.
26. Kilpeläinen TO, Lakka TA, Laaksonen DE, Laukkanen O, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M; Finnish Diabetes Prevention Study Group. Physical activity modifies the effect of SNPs in the SLC2A2 (GLUT2) and ABCC8 (SURI) genes on the risk of developing type 2 diabetes. Physiol Genomics. 2007;31:264-72.
27. Chiasson JL. Prevention of Type 2 diabetes: fact or fiction? Expert Opin Pharmacother. 2007;8:3147-58.
28. Jurado J, Ybarra J, Ferrandiz M, Comerma L, Pou JM. Aminoterminal brain natriuretic peptide is related to the presence of diabetic polyneuropathy independently of cardiovascular disease. Diabetes Care. 2007;30:e86.
29. Sima AA. Pathological mechanisms involved in diabetic neuropathy: can we slow the process? Curr Opin Investig Drugs. 2006;7:324-37.
30. Barrett TG. Differential diagnosis of type 1 diabetes: which genetic syndromes need to be considered? Pediatr Diabetes. 2007;8 Suppl 6:15-23.
31. Molven A, Ringdal M, Nordbø AM, Raeder H, Støv J, Lipkind GM, Steiner DF, Philipson LH, Bergmann I, Aarskog D, Undlien DE, Joner G, Søvik O; the Norwegian Childhood Diabetes Study Group, Bell GI, Njølstad PR. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes. 2008 Jan 11.
32. Fielding AM, Brophy S, Davies H, Williams R. Latent autoimmune diabetes in adults: increased awareness will aid diagnosis. Ann Clin Biochem. 2007;44(Pt 4):321-3.
33. Fernández C, Giménez M, Díaz G, Conget I. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care. 2007;30(9):e96.
34. Cerna M, Kolostova K, Novota P, Romzova M, Cejkova P, Pinterova D, Pruhova S, Treslova L, Andel M. Autoimmune diabetes mellitus with adult onset and type 1 diabetes mellitus in children have different genetic predispositions. Ann N Y Acad Sci. 2007;1110:140-50.
35. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet. 2007;8:657-62.
36. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119(5 Suppl 1):S10-6.
37. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest. 2007;117(5):1226-9.
38. Hattersley AT, Pearson ER. Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes. Endocrinology. 2006;147:2657-63.
39. Holmkvist J, Almgren P, Lyssenko V, lindgren CM, Eriksson KF, Isomaa B, Tuomi T, Nilsson P, Groop L. Common variants in MODY genes and future risk of type 2 diabetes. Diabetes. 2008 Mar. 10.
40. Rutter GA. Generating new candidate genes for neonatal diabetes: functional and genetic studies of insulin secretion in type 2 diabetes. Endocr Dev. 2007;12:75-85.
41. Kaput J, Dawson K. Complexity of type 2 diabetes mellitus data sets emerging from nutrigenomic research: a case for dimensionality reduction? Mutat Res. 2007;622(1-2):19-32.
42. Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract. 2006;12 Suppl 1:34-41.
43. Bresson D, von Herrath M. Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? Autoimmun Rev. 2007;6(5):315-22.
44. Zaia JA. The status of gene vectors for the treatment of diabetes. Cell Biochem Biophys. 2007;48:183-90.
45. Leiter LA. Can thiazolidinediones delay disease progression in type 2 diabetes? Curr Med Res Opin. 2006;22:1193-201.
46. Gerstein HC, Rosenstock J. Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation? Endocrinol Metab Clin North Am. 2005;34:137-54.
47. Brophy S, Brunt H, Davies H, Mannan S, Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev. 2007;18:CD006165.
48. Balasubramanyam A, Garza G, Rodriguez L, Hampe CS, Gaur L. Lernmark A, Maldonado MR. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care. 2006;29(12):2575-9.
49. Timsit J, Bellanné-Chantelot C, Dubois-Laforgue D, Velho G. Diagnosis and management of maturity-onset diabetes of the young. Treat Endocrinol. 2005;4:9-18.
50. Polak M, Cavé H. Neonatal diabetes mellitus: a disease linked to multiple mechanisms. Orphanet J Rare Dis. 2007;2:12.
51. Nield L, Moore HJ, Hooper L, Cruickshank JK, Vyas A, Whittaker V, Summerbell CD. Dietary advice for treatment of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev. 2007 Jul. 18; CD004097.
52. Praet SF, van Loon LJ. Optimizing the therapeutic benefits of exercise in Type 2 diabetes. J Appl Physiol. 2007;103:1113-20.
53. Isermann B, Ritzel R, Zorn M, Schioling T, Nawroth PP. Autoantibodies in diabetes mellitus: current utility and perspectives. Exp Clin Endocrinol Diabetes. 2007;115:483-90.
54. Hinke SA. Finding GAD: early detection of beta-cell injury. Endocrinology. 2007;148:4568-71.
55. Vrabelova Z, Kolouskova S, Böhmova K, Faresjö MK, Sumnik Z, Pechova M, Kverka M, Chudoba D, Zacharovova K, Stadlerova G, Pithova P, Hladikova M, Stechova K. Protein microarray analysis as a tool for monitoring cellular autoreactivity in type 1 diabetes patients and their relatives. Pediatr Diabetes. 2007;8:252-60.
56. Wang X, Jia S, Geoffrey R, Alemzadeh R, Ghosh S, Hessner MJ. Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J Immunol. 2008;180:1929-37.
57. Gadi R, Samaha FF. Dyslipemia in type 2 diabetes mellitus. Curr Diab Rep. 2007;7:228-34.
58. Mikhailidis DP, Press M. The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. Expert Opin Pharmacother, 2007;8:3009-20.
59. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory process in type 2 diabetes: the role of cytokines. Ann N Y Acad Sci. 2006;1084:89-117.
60. Wolf G. Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes. Nutr Rev. 2007;65:251-6.
61. Signorelli SS, Massarino MC, Spandidos DA, Malaponte G. Proinflammatory circulating molecules in peripheral arterial disease. Int J Mol Med. 2007;20:279-86.
62. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681-7.
63. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care. 2008;31(3):517-21.
64. Dungan KM. 1, 5-anhydroglucitol (GlycoMark) as a marker of shortterm glycemic control and glycemic excursions. Expert Rev Mol Diagn. 2008;8:9-19.
65. Takahashi S, Uchino H, Shimizu T, Kanazawa A, Tamura Y, Sakai K, Watada H, Hirose T, Kawamori R, Tanaka Y. Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J. 2007;54(1):139-44.
66. Novak BJ, Blake DR, Meinardi S, Rowland FS, Pontello A, Cooper DM, Galassetti PR. Exhaled methyl nitrate as a noninvasive marker of hyperglycemia in type 1 diabetes. Proc Natl Acad Sci U S A. 2007;104:15613-8.
67. Nguyen HT, Ghevondian N, Nguyen ST, Jones TW. Detection of hypoglycemic episodes in children with type 1 diabetes using an optimal Bayesian neural network algorithm. Conf Proc IEEE Eng Med Biol Soc. 2007;1:3140-3.
68. Pandian PS, Mohanavelu K, Safeer KP, Kotresh TM, Shakunthala DT, Gopal P, Padaki VC. Smart Vest: Wearable multiparameter remote physiological monitoring system. Med Eng Phys. 2007 Sep. 12.
69. Axisa F, Gehin C, Delhomme G, Collet C, Robin O, Dittmar A. Wrist ambulatory monitoring system and smart glove for real time emotional, sensorial and physiological analysis. Conf Proc IEEE Eng Med Biol Soc. 2004;3:2161-4.
70. Ludvigsson J. Immune intervention at diagnosis-should we treat children to preserve beta-cell function? Pediatr Diabetes. 2007;8 Suppl 6:34-9.
71. Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care. 2005;28:1231-9.
72. White RD. Insulin pump therapy (continuous subcutaneous insulin infusion). Prim Care. 2007 34:845-71.
73. Klonoff D. The artificial pancreas: how sweet engineering will solve bitter problems. J Diabetes Sci Technol. 2007;1:72-81.
74. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4-12.
75. Mikhailidis DP, Press M. The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. Expert Opin Pharmacother. 2007;8:3009-20.
76. Hutchison CA 3rd. DNA sequencing: bench to bedside and beyond. Nucleic Acids Res. 2007;35:6227-37.
77. Bottinger EP. Foundations, promises and uncertainties of personalized medicine. Mt Sinai J Med. 2007;74:15-21.
78. Solomon LM, Sieczkiewicz GJ. Impact of the US Patent System on the promise of personalized medicine. Gend Med. 2007;4:187-92.
79. Fox JL. Despite glacial progress, US government signals support for personalized medicine. Nat Biotechnol. 2007;25:489-90.
80. Brenner SE. Common sense for our genomes. Nature. 2007;449:783-4.
81. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL, Shafa F, Stuart JM, Altman RB. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J. 2001;1:167-70.